Hutchmed China Ltd ADR (HCM)

$14.61 -1.13 (-7.18%)
Market Cap 2.74B
Revenue (ttm) 630.20M
Net Income (ttm) 37.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 10.95
Profit Margin 5.99%
Debt to Equity Ratio 0.11
Volume 162,200
Avg Vol 105,836
Day's Range N/A - N/A
Shares Out 174.32M
Stochastic %K 47%
Beta 0.66
Analysts Strong Sell
Price Target $25.75

Latest News on HCM

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

Apr 23, 2025, 8:00 PM EDT - 2 days ago

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

Apr 21, 2025, 8:00 PM EDT - 4 days ago

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Mar 21, 2025, 6:00 AM EDT - 5 weeks ago

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

Mar 20, 2025, 5:30 AM EDT - 5 weeks ago

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

US pharma restrictions won't affect Hutchmed operations, says CEO

Mar 20, 2025, 12:46 AM EDT - 5 weeks ago

US pharma restrictions won't affect Hutchmed operations, says CEO

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Mar 19, 2025, 8:00 PM EDT - 5 weeks ago

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 12:17 PM EDT - 5 weeks ago

HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

Mar 19, 2025, 12:09 PM EDT - 5 weeks ago

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

Mar 19, 2025, 7:00 AM EDT - 5 weeks ago

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Mar 18, 2025, 8:00 PM EDT - 5 weeks ago

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

Mar 6, 2025, 5:00 AM EST - 7 weeks ago

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Mar 5, 2025, 5:00 AM EST - 7 weeks ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED to Announce 2024 Final Results

Feb 19, 2025, 3:30 AM EST - 2 months ago

HUTCHMED to Announce 2024 Final Results

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Jan 13, 2025, 11:00 PM EST - 3 months ago

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

Jan 2, 2025, 7:38 AM EST - 4 months ago

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

Jan 1, 2025, 7:00 PM EST - 4 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales

Jan 1, 2025, 3:42 PM EST - 4 months ago

Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

Jan 1, 2025, 5:46 AM EST - 4 months ago

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Dec 12, 2024, 7:00 PM EST - 4 months ago

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

Dec 11, 2024, 11:00 PM EST - 4 months ago

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

Dec 3, 2024, 7:00 PM EST - 5 months ago

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

Dec 3, 2024, 5:00 AM EST - 5 months ago

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

Nov 28, 2024, 5:30 AM EST - 5 months ago

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

Nov 21, 2024, 11:30 PM EST - 5 months ago

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

Nov 5, 2024, 11:00 PM EST - 6 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

Oct 31, 2024, 4:30 AM EDT - 6 months ago

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

Oct 16, 2024, 12:30 AM EDT - 6 months ago

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

HUTCHMED (China) Ltd (HCM) Shares Up 2.9% on Oct 2

Oct 2, 2024, 12:04 PM EDT - 7 months ago

HUTCHMED (China) Ltd (HCM) Shares Up 2.9% on Oct 2

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Sep 24, 2024, 3:00 AM EDT - 7 months ago

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

Sep 8, 2024, 8:00 PM EDT - 8 months ago

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

Aug 30, 2024, 12:30 AM EDT - 8 months ago

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

Aug 21, 2024, 4:30 AM EDT - 8 months ago

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

Hutchmed Growing Sales By 64% In H1 2024

Aug 9, 2024, 2:08 AM EDT - 9 months ago

Hutchmed Growing Sales By 64% In H1 2024

HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 1:55 PM EDT - 9 months ago

HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

Jul 3, 2024, 8:00 PM EDT - 10 months ago

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

HUTCHMED to Announce 2024 Half-Year Financial Results

Jun 26, 2024, 4:30 AM EDT - 10 months ago

HUTCHMED to Announce 2024 Half-Year Financial Results

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

Jun 24, 2024, 5:30 AM EDT - 10 months ago

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Jun 21, 2024, 4:00 PM EDT - 11 months ago

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

Jun 16, 2024, 8:00 PM EDT - 11 months ago

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

Jun 6, 2024, 8:00 PM EDT - 11 months ago

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

Jun 2, 2024, 8:00 PM EDT - 11 months ago

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

May 23, 2024, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

May 17, 2024, 10:00 AM EDT - 1 year ago

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

May 16, 2024, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

May 13, 2024, 8:00 PM EDT - 1 year ago

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

May 13, 2024, 8:00 PM EDT - 1 year ago

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

Apr 26, 2024, 8:30 AM EDT - 1 year ago

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Apr 5, 2024, 4:30 AM EDT - 1 year ago

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Apr 2, 2024, 1:00 AM EDT - 1 year ago

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Apr 2, 2024, 12:30 AM EDT - 1 year ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status